Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OncoTherapy Science, Inc. Announces Result of Phase Ⅱ/Ⅲ Clinical Trial for Elpamotide


Sunday, 27 Jan 2013 07:00pm EST 

OncoTherapy Science, Inc. announced the result of the phase Ⅱ/Ⅲ clinical trial for elpamotide, which is a neovessel inhibitor. The trail demonstrated the positive effect of elpamotide on pancreatic cancer patients. 

Company Quote

165.0
4.0 +2.48%
11 Jul 2014